BONE MARROW TRANSPLANT IN
CANCER TREATMENT

In cancer treatment, bone marrow transplant refers to hematopoietic stem cell transplantation (HSCT), a procedure where the patient's bone marrow is destroyed with high-dose chemotherapy and radiation, then rebuilt with healthy stem cells from a donor or the patient's own stored cells.

“HSCT has a five-decade evidence base and remains one of the most powerful curative treatments for blood cancers in the right patients.”

• Dose Escalation

  HSCT allows chemotherapy doses far beyond what the bone marrow could normally survive. The marrow is then rescued with stem cell infusion, turning a dose-limiting toxicity into a treatment strategy.

• Graft-Versus-Tumour Effect

  In allogeneic transplant, the donor immune system actively attacks residual cancer cells — a naturally occurring anti-cancer immune surveillance that no other treatment can replicate.

• What HSCT Is Not

  HSCT is a standardised, evidence-based procedure governed by EBMT and CIBMTR protocols. It is completely different from unproven "stem cell treatments" marketed by unlicensed facilities for cancer or anti-aging.

“Important: Hematopoietic stem cell transplantation for cancer is an established, regulated medical procedure with decades of published evidence and worldwide standardization through organizations including the European Bone Marrow Transplantation group (EBMT), the Center for International Blood and Marrow Transplant Research (CIBMTR), and the BMT-CTN. It is entirely distinct from unproven stem cell therapies marketed for cancer, anti-aging, or regenerative purposes at unlicensed clinics. Patients should be alert to this distinction and should only pursue HSCT at accredited transplant centers with documented transplant experience.”

The entire human blood system, every red cell, white cell, and platelet, derives from a small pool of hematopoietic stem cells (HSCs) in the bone marrow. Because this pool is self-renewing and capable of differentiating into all blood lineages, the entire system can be rebuilt from a small number of healthy donor or patient stem cells.

• Erythroid Lineage

  Produces red blood cells and platelets. Red cells survive ~120 days, requiring continuous marrow production.

• Myeloid Lineage

  Produces neutrophils, monocytes, and macrophages — the frontline innate immune defence. Neutrophils survive only ~24 hours.

• Lymphoid Lineage

  Produces T-cells, B-cells, and natural killer cells — the adaptive immune system responsible for targeted pathogen and cancer cell destruction.

The most fundamental distinction in HSCT determines stem cell source, treatment rationale, immunologic consequences, and risk profile. Understanding this difference is critical for patients considering transplant.

Three clinically validated sources of HSCs are used for transplant, each with distinct biological characteristics, advantages, and limitations.

The strongest evidence base for HSCT is in hematological malignancies, the very cancers arising from the blood and immune system. Select solid tumors also benefit from high-dose chemotherapy with autologous rescue.

The entire transplant journey from initial evaluation through engraftment and recovery spans several months. The inpatient phase alone lasts weeks to over a month.

1. 1

   Pre-Transplant Evaluation

   Comprehensive assessment: organ function (cardiac, pulmonary, hepatic, renal), infectious disease screening (CMV, EBV, hepatitis, HIV), dental clearance, fertility preservation, HLA typing, and donor identification.

2. 2

   Stem Cell Collection or Donor Work-Up

   Autologous: G-CSF mobilisation + apheresis to harvest and cryopreserve patient's stem cells. Allogeneic: donor evaluation, mobilisation, and peripheral blood or bone marrow harvest.

3. 3

   Conditioning Regimen

   High-dose chemotherapy ± total body irradiation administered in a dedicated inpatient unit with HEPA filtration. Destroys residual cancer and creates marrow space for new stem cells.

4. 4

   Stem Cell Infusion (Day 0)

   Thawed (autologous) or fresh (allogeneic) stem cells infused intravenously over 1-2 hours. Generally well tolerated; mild flushing or nausea from DMSO preservative may occur.

5. 5

   Engraftment Period (Day 0 to ~Day +30)

   The most critical phase. Bone marrow is empty; intensive support with antibiotics, antifungals, antivirals, transfusions, and nutritional care. Neutrophil engraftment: Day +14-21 (PBSCs). Platelet engraftment: Day +28-35.

6. 6

   Post-Engraftment Recovery and Long-Term Follow-Up

   Immune reconstitution takes months to years. Monitoring for GvHD, infections, relapse, organ function, and late effects. Complete re-vaccination required. Formal long-term follow-up programme essential.

The conditioning regimen — chemotherapy ± radiation given before infusion — is one of the most critical decisions in transplant planning, directly affecting the balance between efficacy and toxicity.

The graft-versus-tumour (GVT) effect is one of the most powerful immunologic phenomena in cancer medicine — a naturally occurring, potentially curative immune attack driven by donor T-cells and NK cells recognising the recipient's cancer as foreign.

“Donor lymphocyte infusions alone can induce remission in relapsed CML with response rates exceeding 70% — proving the GVT effect is genuinely curative.”

• Evidence for GVT

  Relapsed patients after allo-HSCT achieved new remissions from donor lymphocyte infusions alone — no chemo. Identical twin transplants show higher relapse rates than matched unrelated donor transplants, confirming immune-mediated anti-cancer activity.

• The GVT-GvHD Dilemma

  The same donor T-cells that attack cancer also attack normal tissues, causing graft-versus-host disease. Separating GVT from GvHD through selective T-cell depletion and post-transplant immune modulation remains a central research challenge.

• Donor Lymphocyte Infusion (DLI)

  Additional donor T-cell infusions used for molecular or haematological relapse post-transplant, or prophylactic immune reconstitution. Most effective in CML (>70% response in molecular relapse). Main risk is GvHD, carefully dose-titrated at experienced centres.

HSCT is one of the most medically intensive cancer treatments. Understanding risks is essential for informed decision-making — these risks are why transplant must be performed at experienced centres with full supportive care.

• Graft-Versus-Host Disease (GvHD)

  The most distinctive complication of allogeneic HSCT. Acute GvHD (skin, GI, liver) is graded I-IV; Grade III-IV carries significant mortality. Chronic GvHD mimics autoimmune disease and can affect multiple organs. Treated with corticosteroids, ruxolitinib (steroid-refractory), and other immunosuppressants.

• Infectious Complications

  Three risk periods: pre-engraftment (bacterial/fungal from neutropenia), early post-engraftment (viral — CMV, EBV, adenovirus), and late post-transplant (encapsulated bacteria/fungi with chronic GvHD). Requires prophylaxis for PJP, Aspergillus, CMV, and respiratory viruses.

• Sinusoidal Obstruction Syndrome (SOS/VOD)

  Hepatic sinusoid occlusion causing rapid weight gain, ascites, jaundice, and liver failure. Treated with defibrotide for severe cases.

• Other Major Risks

  Primary graft failure (persistent cytopenias requiring second transplant), TA-TMA (endothelial injury with haemolysis and organ dysfunction), pulmonary complications (bronchiolitis obliterans, IPS), secondary malignancies (PTLD, therapy-related MDS/AML), and transplant-related mortality (2-5% autologous; 5-20%+ allogeneic).

For allogeneic HSCT, donor compatibility is established by matching human leukocyte antigens (HLA) — cell surface proteins the immune system uses to distinguish self from non-self. A 10/10 match across HLA-A, -B, -C, -DRB1, and -DQB1 is the gold standard.

1. 1

   Matched Sibling Donor (Best Option)

   25% chance any sibling is a full HLA match. Lowest GvHD risk and best outcomes. Always tested first.

2. 2

   Matched Unrelated Donor (MUD)

   International registries (WMDA, DKMS, Be The Match) hold 40M+ donors. A 10/10 MUD is the next best option when no sibling match exists.

3. 3

   Haploidentical Donor

   A partially matched family member (parent, child, half-matched sibling). Enabled by post-transplant cyclophosphamide for GvHD control. Critical for ethnic minorities with limited registry representation.

4. 4

   Cord Blood

   Immunologically naive T-cells allow wider HLA disparity. Stored in public cord blood banks. Especially valuable for patients without other donor options.

• 60-70%5-Year Survival (AML CR1, Matched Sibling)Young patients with AML in first complete remission — best-case scenario.
• 3-4 yrMedian PFS (Myeloma, Auto-HSCT)With contemporary induction including daratumumab-based regimens.
• 40M+Registered Donors WorldwideCoordinated through WMDA, DKMS, Be The Match, and national registries.
• >70%DLI Response Rate (CML Molecular Relapse)Demonstrating the curative power of the graft-versus-tumour effect.
• 14–21 daysMedian time to neutrophil engraftmentIn many modern stem cell transplant series, white blood cell recovery begins within about two to three weeks after transplant, making this one of the most important early recovery milestones.
• ~60%ong-term survival in selected adult ALL transplant patientsModern allogeneic transplant can deliver durable survival in appropriately selected adults with acute lymphoblastic leukemia, especially when performed in remission at experienced centers.

Centre expertise, transplant volume, and infrastructure quality directly and measurably impact transplant outcomes. Higher-volume centres achieve better engraftment rates, lower transplant-related mortality, and improved survival.

• Medical Records & Eligibility Review

  CancerFax helps patients compile, translate, and submit medical records for transplant eligibility assessment at international centres.

• Donor Search Coordination

  Initiation and coordination with international donor registries (WMDA network), including haploidentical and cord blood options.

• Centre Selection & Referral

  Identification of the most appropriate transplant centre based on disease type, donor availability, conditioning requirements, and geographic accessibility.

• Pre-Transplant Consultation

  Arrangement of specialist consultations and evaluations at international transplant centres before travel.

• Travel, Accommodation & Cost Planning

  Logistical support for patients and accompanying family members, including cost estimation and financial planning.

• Post-Transplant Shared Care

  Coordination between the transplant centre and home oncologist for long-term follow-up, vaccination schedules, and GvHD management.

Each page provides deeper coverage of a specific topic within bone marrow transplant for cancer treatment.

Questions Every Patient Should Ask About Stem Cell Transplant

These questions are designed to help patients engage actively and effectively with their hematologist, transplant physician, or a CancerFax-connected specialist at every stage of the HSCT decision-making and planning process.